Virtual medical scribing software has revolutionized patient care and made documentation more efficient in the healthcare industry. When selecting virtual medical scribing software, looking for ...

Experts Publish Consensus on CT for Prosthetic Heart Valve Assessment. The consensus document was jointly published today in Radiology: Cardiothoracic Imaging, a journal of the Radiological Society of ...

The new 133,500-square-foot headquarters at 12001 Exit 5 Parkway will house an advanced pharmacy featuring category III, 503A/503B compounding capabilities alongside integrated telemedicine services ...

Experts from multiple medical societies have published a consensus document to provide guidance on how best to use cardiac CT for prosthetic heart valve assessment. The consensus document was jointly ...

VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program. Partnership Combines VERAXA’s Proprietary ADC Technology with OmniAb’s Antibody ...

The launch marks a significant step in Seed’s evolution from a DTC disruptor to a leading omnichannel brand, amplifying its strategy to make clinically validated microbiome science accessible wherever ...

Setting the Scene: My Tangled Hair Affair Truth bomb right off the bat: my hair was a stubborn mule. For years, I faced mornings wrestling with locks that behaved like defiant teenagers refusing ...

The study “Evaluating a cutting‑edge augmented reality‑supported navigation system for spinal instrumentation”1 led by Prof. Dr. med. Bernhard Meyer, evaluates the efficiency, accuracy, and ...

BioArctic to Initiate Next Cohorts In Exidavnemab Phase 2a Study After Positive Safety Review. The Phase 2a study EXIST (EXIdavnemab Synucleinopathy Trial), is a randomized, double-blinded, ...

Seed, a microbiome science company, today announced the nationwide retail launch of its clinically validated microbiome innovations at Sprouts Farmers Market. Beginning this week, Seed’s DS-01® Daily ...

The Phase 2a study EXIST (EXIdavnemab Synucleinopathy Trial), is a randomized, double-blinded, placebo-controlled study to evaluate the safety and tolerability of exidavnemab and its pharmacokinetic ...

InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard ® Prime carotid stent system for the prevention of stroke, today announced the company has received CE Mark approval under the European Medical ...